June 29, 2023
Astellas Pharma said on June 28 that its oral nonhormonal therapy fezolinetant, being developed for moderate to severe vasomotor symptoms (VMS) due to menopause, yielded positive topline data in the PIIIb DAYLIGHT study conducted in Europe, Canada and Turkey. The...read more